Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. - Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Chen Z; Thomas RB; Kosloski MP; Dubost-Brama A; Prescilla R; Bansal A; Levit NA (Dermatology and therapy, 2023)